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FPRL1 Receptor Agonist Peptides Prevent Etoposide-Induced
Alopecia in Neonatal Rats
To the Editor:
In previous study, we showed that chemotactic peptide
formyl-Met-Leu-Phe (fMLP) given intraperitoneally at a dose
of 30 mg per kg for consecutive 4 d suppressed alopecia
induced by an anti-cancer drug etoposide in neonatal rat
model (Tsuruki et al, 2004). Involvement of low-affinity
subtype of fMLP receptor in the anti-alopecia effect is
suggested, since the dose is far much higher than those for
various effects of fMLP (  10 mg per kg) (Bureau et al,
1989; Celardo et al, 1997). Although fMLP receptor
subtypes in rat have never been identified, formylpeptide
receptor (FPR) and FPR like-1 receptor (FPRL1R) are known
as high- and low-affinity receptor subtypes, respectively, in
human (Le et al, 2002). In this study, we found that MMK-1
and the mitochondrial peptide (MHC binding peptide), which
are selective agonists for human FPRL1R (Klein et al, 1998;
Chiang et al, 2000), exerted anti-alopecia effect in rat.
MMK-1 (LESIFRSLLFRVM) and the mitochondrial peptide
(MYFINILTL) were prepared by solid-phase peptide synthesi-
zer (PS3, Protein Technologies, Inc, Tuscon, Arizona) accord-
ing to the 9-fluoroenyl methoxycarbonyl (Fmoc) method.
Peptides were purified with reversed-phase high-performance
liquid chromatography (HPLC) on ODS column (Cosmosil
5C18-AR-II, 20  250 mm, Nacalai Tesque, Inc, Kyoto, Japan).
Experimental protocols involving laboratory animals were
approved by the ethical committee of the Graduate School of
Agriculture, Kyoto University. In this study, reagents were
dissolved in saline and intraperitoneally injected in a volume of
10 mL per kg. Etoposide (Nippon Kayaku Co, Ltd, Tokyo,
Japan) was injected at a dose of 1.5 mg per kg i.p. for 3 d and
alopecia was induced about 7 d after the last injection in
neonatal rat model. MMK-1 given intraperitoneally at a dose of
10 mg per kg for consecutive 4 d completely suppressed
alopecia induced by etoposide (Fig 1A). The mitochondrial
peptide also exhibited anti-alopecia effect at a dose of 10 mg
per kg intraperitoneally for 4 d (Fig 1B). Thus, FPRL1R agonists
are effective in preventing alopecia at lower dose than that of
fMLP. Especially, the minimum effective dose of MMK-1 (10
mg per kg) is one of 10 that of fMLP (30 mg per kg) in molar
ratio. These results suggest that a rat homolog of human
FPRL1R, if any, might be involved in anti-alopecia effects.
Next, we histochemically analyzed dorsal skin of etopo-
side-treated rats, which alopecia was prevented by MMK-1.
Loss of the number of hair, thinning of the skin layer, and
thickening of epidermis induced by etoposide were sup-
pressed by MMK-1 at a dose of 10 mg per kg intra-
peritoneally for 4 d (Fig 1C). The shape of the hair follicles in
rats given both etoposide and MMK-1, as well as control
rats injected only with saline was normal. MMK-1 did not
cause inflammatory infiltration of macrophages and granu-
locytes to skin tissues under this condition. Appearance of
dorsal skin sections obtained from etoposideþMMK-
1-treated rats were similar to that from etoposideþ fMLP-
treated rats of previous study (Tsuruki et al, 2004).
We studied post-receptor mechanism for the anti-
alopecia effects of fMLP and MMK-1. N-formylpeptides
Figure1
Protective effects of FPRL1R agonists against etoposide-induced
alopecia. Etoposide was injected at a dose of 1.5 mg per kg
intraperitoneally for 3 consecutive d to 11-d-old rats. (A) MMK-1 (10
mg per kg) or (B) the mitochondrial peptide (10 mg per kg) was
administered intraperitoneally for 4 d beginning 1 d before the first
etoposide injection. Pictures were taken 7 d after the last etoposide
injection (C) Light micrographs of hematoxilin-eosin stained dorsal skin
sections from neonatal rats treated with (a) saline, (b) etoposide (1.5 mg
per kg, i.p. for 3 d) or (c) etoposide (1.5 mg per kg, i.p. for 3 d) þ MMK-
1 (10 mg per kg, i.p. for 4 d). These sections were treated with
hematoxilin-eosin (HE) staining. Scale bars: 100 mm.
Abbreviations: fMLP, N-formyl-methionyl-leucyl-phenylalanine;
FPR, formylpeptide receptor; FPRL1R, FPR like 1 receptor
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are known to promote histamine release (Hook et al, 1976).
Thus, the effects of histamine antagonists were assessed.
Given intraperitoneally at a dose of 10 mg per kg for 4 d,
histamine H1 receptor antagonists pyrilamine (Sigma
Chemical Co, St Louis, Missouri), blocked the protective
effects of fMLP (Bachem AG, Bubendorf, Switzerland, 30
mg per kg i.p. for 4 d) and MMK-1 (10 mg per kg i.p. for 4 d)
against alopecia induced by etoposide (Fig 2A and B). A
histamine H2 receptor antagonist cimetidine (Sumitomo
Pharmaceuticals Co, Ltd, Osaka, Japan, 10 mg per kg i.p.
for 4 d) also inhibited the anti-alopecia effects of fMLP (Fig
2C) or MMK-1 (data not shown). Pyrilamine and cimetidine
themselves did not induce alopecia. These suggest that
both histamine H1 and H2 receptors are involved in the anti-
alopecia effects of fMLP agonists. These are also the first
evidence to indicate involvement of histamine in prevention
of alopecia induced by anti-cancer drugs.
Histamine released after binding of fMLP agonists to
FPRL1R might induce anti-alopecia effect via histamine
receptors.
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Figure 2
Inhibition of the anti-alopecia effect of fMLP
and MMK-1 by a histamine H1 antagonist.
Etoposide was injected at a dose of 1.5 mg per
kg intraperitoneally for 3 consecutive d to 11-d-
old rats. (A and C) fMLP (30 mg per kg i.p. for 4
d) or (B) MMK-1 (10 mg per kg i.p. for 4 d) was
administered intraperitoneally for 4 consecutive
d beginning 1 d before the first etoposide
injection. (A and B) Pyrilamine (10 mg per kg
i.p. for 4 d) or (C) cimetidine (10 mg per kg i.p. for
4 d) was injected alone or simultaneously with
fMLP or MMK-1. Pictures were taken 7 d after
the last etoposide injection.
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